NCT01267955 2026-04-13
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT02453620 2026-04-13
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06744712 2026-03-25
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Wake Forest University Health Sciences
Phase NA Not yet recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT01165333 2026-03-16
CILENT
Centre Oscar Lambret
Phase 1 Completed
NCT06489041 2026-02-02
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Wake Forest University Health Sciences
Phase NA Recruiting
NCT01196936 2026-01-05
LDTam
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT02048813 2025-11-28
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01012817 2025-09-15
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02581930 2025-09-08
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02399371 2025-06-11
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Active not recruiting
NCT06511401 2025-04-27
C-PAIN
University of Chicago
Phase NA Recruiting
NCT02717507 2025-04-23
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Children's Oncology Group
Phase 2 Completed